Leukocyte and endothelial angiotensin II type 1 receptors and microvascular thrombotic and inflammatory responses to hypercholesterolemia

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 26, Issue 2, 2006, Pages 240-241

  Alexander, R Wayne ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN II; ANGIOTENSIN RECEPTOR ANTAGONIST; EXP 3179; LOSARTAN; REACTIVE OXYGEN METABOLITE; UNCLASSIFIED DRUG; VALSARTAN; ANGIOTENSIN 1 RECEPTOR;

ATHEROSCLEROSIS; EDITORIAL; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERLIPIDEMIA; INSULIN RESISTANCE; LEUKOCYTE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; IMMUNOLOGY; METABOLISM; MICROCIRCULATION; NOTE; THROMBOSIS; VASCULAR ENDOTHELIUM; VASCULITIS;

ENDOTHELIUM, VASCULAR; HUMANS; HYPERCHOLESTEROLEMIA; LEUKOCYTES; MICROCIRCULATION; RECEPTOR, ANGIOTENSIN, TYPE 1; THROMBOSIS; VASCULITIS;

EID: 33644857993     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.0000199680.42737.ca     Document Type: Editorial

References (23)

1. Chobanian AV, Alexander RW. Exacerbation of atherosclerosis by hypertension: potential mechanisms and clinical implications. Arch Intern Med. 1996;156:1919-1920.
2. HOPE Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med. 2000;342:145-153.
3. Dahlof B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, Fyhrquist F, Ibsen H, Kristiansson K, Lederballe-Pedersen O, Lindholm luteinizing hormone (LH), Nieminen MS, Omvik P, Oparil S, Wedel H, Group LS. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.[see comment]. Lancet. 2002;359: 995-1003.
4. Griendling KK, Murphy TJ, Alexander RW. Molecular biology of the renin-angiotensin system. Circulation. 1993;87:1816-1828.
5. Nickenig G Central role of the AT(1)-receptor in atherosclerosis. J Hum Hypertens. 2002;16(suppl 3):S26-S33.
6. Griendling KK, Harrison DG, Alexander RW. Biology of the Vessel Wall. In: Fuster V, Alexander RW, O'Rourke RA, et al, eds. Hurst's The Heart. 11th ed. New York, NY: McGraw-Hill; 2004.
7. Mueller CF, Laude K, McNally JS, Harrison DG. ATVB in focus: redox mechanisms in blood vessels. Arterioscler Thromb Vasc Biol. 2005;25: 274-278.
8. Cai H, Li Z, Dikalov S, Holland SM, Hwang J, Jo H, Dudley SC Jr, Harrison DG. NAD(P)H oxidase-derived hydrogen peroxide mediates endothelial nitric oxide production in response to angiotensin II. J Biol Chem. 2002;277:48311-48317.
9. Wellen KE, Hotamisligil GS. Obesity-induced inflammatory changes in adipose tissue. J Clin Invest. 2003;112:1785-1788.
10. Zeiher AM, Drexler H, Wollschlager H, Just H. Endothelial dysfunction of the coronary microvasculature is associated with coronary blood flow regulation in patients with early atherosclerosis. Circulation. 1991;84: 1984-1992.
11. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S, RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.[see comment]. N Engl J Med. 2001;345:861-869.
12. Tailor A, Granger DN. Hypercholesterolemia promotes P-selectin-dependent platelet-endothelial cell adhesion in postcapillary venules. Arterioscler Thromb Vasc Biol. 2003;23:675-680.
13. Stokes KY, Clanton EC, Russell JM, Ross CR, Granger DN. NAD(P)H oxidase-derived superoxide mediates hypercholesterolemia-induced leukocyte-endothelial cell adhesion. Circ Res. 2001;88:499-505.
14. Piqueras L, Kubes P, Alvarez A, O'Connor E, Issekutz AC, Esplugues JV, Sanz MJ. Angiotensin II induces leukocyte-endothelial cell interactions in vivo via AT(1) and AT(2) receptor-mediated P-selectin upregulation. Circulation. 2000;102:2118-2123.
15. Petnehazy T, Stokes KY, Russell JM, Granger DN. Angiotensin II type-1 receptor antagonism attenuates the inflammatory and thrombogenic responses to hypercholesterolemia in venules.[see comment]. Hypertension. 2005;45:209-215.
16. Stokes KY, Clanton EC, Clements KP, Granger DN. Role of INF-gamma in hypercholesterolemia-induced leukocyte-endothelial cell adhesion. Circulation. 2003;107:2140-2145.
17. Tailor A, Granger DN. Hypercholesterolemia promotes leukocyte-dependent platelet adhesion in murine postcapillary venules. Microcirculation. 2004;11:597-603.
18. Petnehazy T, Stokes KY, Wood KC, Russell JM. Role of blood cell-associated AT1 receptors in the microvascular responses to hypercholesterolemia. Arterioscler Thromb Vasc Biol. 2006;26:313-318.
19. El Bekay R, Alvarez M, Monteseirin J, Alba G, Chacon P, Vega A, Martin-Nieto J, Jimenez J, Pintado E, Bedoya FJ, Sobrino F. Oxidative stress is a critical mediator of the angiotensin II signal in human neutrophils: involvement of mitogen-activated protein kinase, calcineurin, and the transcription factor NF-kappaB. Blood. 2003;102:662-671.
20. Muller DN, Dechend R, Mervaala EM, Park JK, Schmidt F, Fiebeler A, Theuer J, Breu V, Ganten D, Haller H, Luft FC. NF-kappaB inhibition ameliorates angiotensin II-induced inflammatory damage in rats. Hypertension. 2000;35:193-201.
21. Nickenig G, Jung O, Strehlow K, Zolk O, Linz W, Scholkens BA, Bohm M. Hypercholesterolemia is associated with enhanced angiotensin AT1-receptor expression. Am J Physiol. 1997;272:H2701-H2707.
22. Nickenig G, Sachinidis A, Michaelsen F, Bohm M, Seewald S, Vetter H. Upregulation of vascular angiotensin II receptor gene expression by low-density lipoprotein in vascular smooth muscle cells. Circulation. 1997;95:473-478.
23. Nickenig G. Should angiotensin II receptor blockers and statins be combined? Circulation. 2004;110:1013-1020.